pamidronate has been researched along with Prostatic Neoplasms in 69 studies
Prostatic Neoplasms: Tumors or cancer of the PROSTATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pamidronate disodium failed to demonstrate a significant overall treatment benefit compared with placebo in palliation of bone pain or reduction of SREs." | 9.10 | Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. ( Kowalski, MO; Petrone, S; Seaman, JJ; Small, EJ; Smith, MR, 2003) |
| " We present here the first case of an acute retinal pigment epithelial detachment associated with pamidronate infusion in a 59-year-old patient with metastatic prostate cancer." | 7.75 | Acute retinal pigment epithelial detachment secondary to pamidronate administration. ( Alexandrescu, DT; Dasanu, CA, 2009) |
| "Pamidronate disodium failed to demonstrate a significant overall treatment benefit compared with placebo in palliation of bone pain or reduction of SREs." | 5.10 | Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. ( Kowalski, MO; Petrone, S; Seaman, JJ; Small, EJ; Smith, MR, 2003) |
| "Four intravenous regimens of pamidronate (Aredia) were evaluated for palliative treatment of bone metastases in 2 randomized open-label trials in patients with breast cancer (n = 61) or prostate cancer (n = 58)." | 5.07 | Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer. ( Glover, D; Grabelsky, S; Harvey, H; Lipton, A; Macerata, R; Seaman, J; Zelenakas, K, 1994) |
| "Zoledronic acid seems to be the most efficacious bisphosphonate for reducing the risk of SREs in patients with cancer of the breast or prostate and those with multiple myeloma." | 4.89 | Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis. ( Brown, J; Fullarton, JR; Palmieri, C, 2013) |
| "Zoledronic acid (Zometa is a third-generation nitrogen-containing parenteral bisphosphonate indicated for the treatment of bone metastases due to solid tumours or multiple myeloma and for hypercalcaemia of malignancy (HCM)." | 4.84 | Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases. ( McKeage, K; Plosker, GL, 2008) |
| " In multiple myeloma, one study with oral clodronate has reported a decrease in bone events and two other studies, one with intravenous pamidronate and the other with oral clodronate have both reported a decrease in skeletal events and bone pain." | 4.80 | [Bisphosphonates and bone metastases]. ( Berthaud, P; Jadaud, E; Lortholary, A, 1999) |
| "To determine the protective effect of apigenin against growth inhibition of normal epithelial human prostatic (PNT2), transgenic adenocarcinoma of mouse prostate (TRAMP-C1) and metastatic melanoma cells (B16F10) in combined treatments with bisphosphonates and ionizing radiation (IR)." | 3.79 | Effects of bisphosphonates in combination with ionizing radiation and antioxidants on the growth of prostate and melanoma cells lines. ( Achel, DG; Alcaraz, M; Alcaraz-Saura, M; Olivares, A, 2013) |
| " Osteonecrosis of the jaw is an uncommon but serious event in patients receiving monthly intravenous bisphosphonates or denosumab." | 3.76 | Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases. ( Aapro, M; Costa, L; Saad, F, 2010) |
| " We present here the first case of an acute retinal pigment epithelial detachment associated with pamidronate infusion in a 59-year-old patient with metastatic prostate cancer." | 3.75 | Acute retinal pigment epithelial detachment secondary to pamidronate administration. ( Alexandrescu, DT; Dasanu, CA, 2009) |
| "Osteonecrosis of the jaw (ONJ) has been associated recently with the use of pamidronate and zoledronic acid." | 3.73 | Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. ( Anagnostopoulos, A; Bamia, C; Bamias, A; Bozas, G; Dimopoulos, MA; Gika, D; Kastritis, E; Koutsoukou, V; Melakopoulos, I; Moulopoulos, LA; Papadimitriou, C; Terpos, E, 2005) |
| " Pamidronate, an inhibitor of bone resorption used primarily in the management of tumor-induced hypercalcemia and Paget's disease, is reported to cause conjunctivitis, anterior uveitis, and infrequently episcleritis and scleritis." | 3.72 | Posterior uveitis: an under-recognized adverse effect of pamidronate: 2 case reports. ( Claes, C; Haverbeke, G; Pertile, G; Zeyen, T, 2003) |
| " Pamidronate (Aredia(TM)) is the most widely evaluated bisphosphonate and is recommended for most patients with multiple myeloma or breast cancer with bone metastases." | 3.70 | Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM). ( Coleman, RE, 2000) |
| "For patients with prostate cancer, the choice between these 2 bisphosphonates must be balanced between the shorter infusion time of zoledronic acid versus its increased costs." | 2.75 | Risk of skeletal-related events in patients with advanced prostate cancer treated with pamidronate or zoledronic acid. ( Chan, J; Hui, RL; Schottinger, JE; Spence, MM, 2010) |
| "Hypogonadism is associated with osteoporosis in men." | 2.70 | Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men. ( Fallon, MA; Finkelstein, JS; Leder, BZ; Lee, ML; Smith, MR, 2001) |
| "Treatment with pamidronate resulted in a 7." | 2.70 | The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. ( Bryant, C; De Souza, P; Diamond, TH; Kersley, JH; Lynch, WJ; Smith, A; Winters, J, 2001) |
| " In a randomized phase III trial of 377 patients with multiple myeloma, Aredia was administered in a dosage of 90 mg i." | 2.68 | The role of bisphosphonates in the treatment of bone metastases--the U.S. experience. ( Harvey, HA; Lipton, A, 1996) |
| "In view of previous animal studies showing that pamidronate (Aredia) can cause renal damage, and human data indicating that pamidronate in doses of 60-90 mg is more effective in the control of tumor-induced hypercalcemia than when given at lower doses, we decided to investigate whether pamidronate 90 mg infused over 60 minutes at weekly intervals had any adverse effects on renal function in patients with bone metastases." | 2.67 | Intravenous pamidronate: infusion rate and safety. ( Coleman, T; Collinson, M; Ford, JM; Madsen, EL; Tyrrell, CJ, 1994) |
| "Treatment with zoledronic acid probably neither reduces nor increases the proportion of participants with pain response when compared to no treatment/placebo (risk ratio (RR) 1." | 2.66 | Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. ( Adams, A; Heidenreich, A; Jakob, T; Kuhr, K; Macherey, S; Monsef, I; Skoetz, N; Tesfamariam, YM, 2020) |
| "In men, prostate cancer is the most common non-cutaneous malignancy and the second most common cause of cancer death." | 2.48 | Bone-targeted agents: preventing skeletal complications in prostate cancer. ( Morgans, AK; Smith, MR, 2012) |
| "Zoledronic acid (4 mg) has been compared to placebo in a randomized Phase III trial involving 422 men with hormone-refractory prostate cancer metastatic to bone." | 2.41 | The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. ( Gleason, D; Gordon, D; Kowalski, MO; Lipton, A; Reitsma, D; Rosen, L; Saad, F; Seaman, J; Small, E; Smith, M, 2002) |
| " Although newer bisphosphonates are more potent, oral bioavailability remains < 1%." | 2.41 | Oral bisphosphonates: A review of clinical use in patients with bone metastases. ( Berenson, J; Hortobagyi, G; Lipton, A; Major, PP, 2000) |
| "Experts in the field were approached." | 2.40 | Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. ( Bloomfield, DJ, 1998) |
| "Comparative analysis of different cancer patients helps the treating oncologist/dentist to identify patients with a more imminent risk to develop an ONJ (i." | 1.42 | Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients. ( Felsenberg, D; Gabbert, TI; Hoffmeister, B, 2015) |
| "Nineteen patients were diagnosed with breast cancer and 18 with prostate cancer." | 1.40 | Time and labor costs associated with administration of intravenous bisphosphonates for breast or prostate cancer patients with metastatic bone disease: a time and motion study. ( Angelis, CD; Burke, N; Giotis, A; Goeree, R; Habib, M; Hopkins, RB; Pasetka, M; Xie, F, 2014) |
| "Majority of patients with prostate cancer develop bone metastases which lead to serious skeletal complications." | 1.35 | [Efficiency of second-generation bisphosphonate in treating patients with prostate cancer and bone metastases]. ( Ali-zade, AM; Kerimov, AKh; Musaev, TN, 2008) |
| "Patients with breast cancer demonstrated a reduced risk for ONJ development, which turned out to be nonsignificant after adjustment for other variables." | 1.35 | Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. ( Andreadis, CG; Antoniades, K; Boukovinas, I; Katodritou, E; Kitikidou, K; Koloutsos, GE; Kyrgidis, A; Paraskevopoulos, P; Teleioudis, Z; Triaridis, S; Vahtsevanos, K; Verrou, E; Zervas, K, 2009) |
| "This indirect inhibition of prostate cancer cells via bone cells could be beneficial in treating prostate cancer patients with bone metastases." | 1.35 | Indirect antitumor effects of bisphosphonates on prostatic LNCaP cells co-cultured with bone cells. ( Kawashima, H; Kuratsukuri, K; Matsumura, K; Matsuyama, M; Nakatani, T; Ohnishi, K; Tanaka, T; Yoshimura, R, 2009) |
| "Pamidronate treatment exhibited anti-tumor effects that were reflected by decreases in serum PTHrP, OPG, and by GFP and radiological imaging procedures." | 1.33 | Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP. ( Barken, I; Burton, DW; Deftos, LJ; Geller, J; Hastings, RH; Hoffman, RM; Jiang, P; Yang, M, 2005) |
| "Sixty-two (52." | 1.33 | Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. ( Broumand, V; Fortin, M; Marx, RE; Sawatari, Y, 2005) |
| "Long-term pamidronate treatment of prostate cancer bone metastases does not generally affect the ability to detect bone metastases with Tc99 MDP bone scintigraphy." | 1.32 | Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. ( Higano, CS; King, SH; Ott, SM; Roudier, MP; True, LD; Vessella, RL; Vesselle, H, 2003) |
| "Ten patients (46%) were affected by breast carcinoma, 7 (32%) by prostate carcinoma and 5 (22%) by multiple myeloma." | 1.32 | Safety of long-term administration of bisphosphonates in elderly cancer patients. ( Bollina, R; Conti, G; Di Mari, A; Ferrau', F; Mauceri, G; Repetto, L; Tralongo, P, 2004) |
| "Conversely, in Paget's disease and prostate cancer-induced bone metastases, conditions characterized by focal increased bone turnover, alpha L CTX levels were more elevated than those of age-related CTX forms, resulting in increased ratios between native and age-modified CTX." | 1.32 | Investigation of bone disease using isomerized and racemized fragments of type I collagen. ( Body, JJ; Christgau, S; Christiansen, C; Cloos, PA; Delmas, P; Engsig, M; Fledelius, C; Garnero, P, 2003) |
| "N-BPs induce apoptosis in prostate cancer via a caspase dependent mechanism." | 1.32 | Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. ( Clarke, IA; Colston, KW; Kirby, RS; Oades, GM; Senaratne, SG, 2003) |
| "Although both drugs reduced prostate cancer cell growth in the presence of serum, zoledronate was more potent under these conditions, disrupting growth at doses as low as 25 microM in the presence of 5% fetal bovine serum." | 1.31 | Bisphosphonate treatment inhibits the growth of prostate cancer cells. ( Fong, EM; Guenette, RS; Lee, MV; Singer, FR, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (2.90) | 18.7374 |
| 1990's | 14 (20.29) | 18.2507 |
| 2000's | 38 (55.07) | 29.6817 |
| 2010's | 14 (20.29) | 24.3611 |
| 2020's | 1 (1.45) | 2.80 |
| Authors | Studies |
|---|---|
| Jakob, T | 1 |
| Tesfamariam, YM | 1 |
| Macherey, S | 1 |
| Kuhr, K | 1 |
| Adams, A | 1 |
| Monsef, I | 1 |
| Heidenreich, A | 1 |
| Skoetz, N | 1 |
| Santolaria, T | 1 |
| Robard, M | 1 |
| Léger, A | 1 |
| Catros, V | 1 |
| Bonneville, M | 1 |
| Scotet, E | 1 |
| Alcaraz, M | 1 |
| Olivares, A | 1 |
| Achel, DG | 1 |
| Alcaraz-Saura, M | 1 |
| Hahn, NM | 1 |
| Yiannoutsos, CT | 1 |
| Kirkpatrick, K | 1 |
| Sharma, J | 1 |
| Sweeney, CJ | 1 |
| Palmieri, C | 1 |
| Fullarton, JR | 1 |
| Brown, J | 1 |
| Oster, G | 1 |
| Lamerato, L | 1 |
| Glass, AG | 1 |
| Richert-Boe, KE | 1 |
| Lopez, A | 1 |
| Chung, K | 1 |
| Richhariya, A | 1 |
| Dodge, T | 1 |
| Wolff, GG | 1 |
| Balakumaran, A | 1 |
| Edelsberg, J | 1 |
| Xie, F | 1 |
| Hopkins, RB | 1 |
| Burke, N | 1 |
| Habib, M | 1 |
| Angelis, CD | 1 |
| Pasetka, M | 1 |
| Giotis, A | 1 |
| Goeree, R | 1 |
| Gabbert, TI | 1 |
| Hoffmeister, B | 1 |
| Felsenberg, D | 1 |
| Dasanu, CA | 1 |
| Alexandrescu, DT | 1 |
| Musaev, TN | 1 |
| Kerimov, AKh | 1 |
| Ali-zade, AM | 1 |
| Tanaka, T | 2 |
| Kawashima, H | 2 |
| Ohnishi, K | 1 |
| Matsumura, K | 1 |
| Yoshimura, R | 1 |
| Matsuyama, M | 1 |
| Kuratsukuri, K | 2 |
| Nakatani, T | 2 |
| Vahtsevanos, K | 1 |
| Kyrgidis, A | 1 |
| Verrou, E | 1 |
| Katodritou, E | 1 |
| Triaridis, S | 1 |
| Andreadis, CG | 1 |
| Boukovinas, I | 1 |
| Koloutsos, GE | 1 |
| Teleioudis, Z | 1 |
| Kitikidou, K | 1 |
| Paraskevopoulos, P | 1 |
| Zervas, K | 1 |
| Antoniades, K | 1 |
| Tatsuda, Y | 2 |
| Iguchi, K | 2 |
| Usui, S | 2 |
| Suzui, M | 1 |
| Hirano, K | 2 |
| Crawford, BS | 1 |
| McNulty, RM | 1 |
| Kraut, EH | 1 |
| Turowski, RC | 1 |
| Spence, MM | 1 |
| Hui, RL | 1 |
| Chan, J | 1 |
| Schottinger, JE | 1 |
| ten Dam, MA | 1 |
| Hilbrands, LB | 1 |
| Wetzels, JF | 1 |
| Aapro, M | 1 |
| Saad, F | 3 |
| Costa, L | 1 |
| Berenson, JR | 1 |
| Morgans, AK | 1 |
| Smith, MR | 5 |
| Cloos, PA | 1 |
| Fledelius, C | 1 |
| Christgau, S | 1 |
| Christiansen, C | 1 |
| Engsig, M | 1 |
| Delmas, P | 1 |
| Body, JJ | 1 |
| Garnero, P | 1 |
| Lipton, A | 4 |
| Small, E | 1 |
| Gleason, D | 1 |
| Gordon, D | 1 |
| Smith, M | 1 |
| Rosen, L | 1 |
| Kowalski, MO | 2 |
| Reitsma, D | 1 |
| Seaman, J | 2 |
| Barthel, HR | 1 |
| Major, PP | 2 |
| Cook, R | 1 |
| Roudier, MP | 1 |
| Vesselle, H | 1 |
| True, LD | 1 |
| Higano, CS | 1 |
| Ott, SM | 1 |
| King, SH | 1 |
| Vessella, RL | 1 |
| Oades, GM | 1 |
| Senaratne, SG | 1 |
| Clarke, IA | 1 |
| Kirby, RS | 1 |
| Colston, KW | 1 |
| Subramanian, PS | 1 |
| Kerrison, JB | 1 |
| Calvert, PC | 1 |
| Miller, NR | 1 |
| Herring, P | 1 |
| Ingels, J | 1 |
| Carbone, LD | 1 |
| Barrow, KD | 1 |
| Osborn, D | 1 |
| Dietzen, DJ | 1 |
| Pifer, L | 1 |
| Small, EJ | 1 |
| Seaman, JJ | 1 |
| Petrone, S | 1 |
| Kelly, WK | 1 |
| Steineck, G | 1 |
| Haverbeke, G | 1 |
| Pertile, G | 1 |
| Claes, C | 1 |
| Zeyen, T | 1 |
| Altundag, O | 1 |
| Altundag, K | 1 |
| Burton, DW | 2 |
| Geller, J | 2 |
| Yang, M | 2 |
| Jiang, P | 1 |
| Barken, I | 1 |
| Hastings, RH | 2 |
| Hoffman, RM | 2 |
| Deftos, LJ | 2 |
| Tralongo, P | 1 |
| Repetto, L | 1 |
| Di Mari, A | 1 |
| Mauceri, G | 1 |
| Bollina, R | 1 |
| Ferrau', F | 1 |
| Conti, G | 1 |
| Tanvetyanon, T | 1 |
| Marx, RE | 1 |
| Sawatari, Y | 1 |
| Fortin, M | 1 |
| Broumand, V | 1 |
| Bamias, A | 1 |
| Kastritis, E | 1 |
| Bamia, C | 1 |
| Moulopoulos, LA | 1 |
| Melakopoulos, I | 1 |
| Bozas, G | 1 |
| Koutsoukou, V | 1 |
| Gika, D | 1 |
| Anagnostopoulos, A | 1 |
| Papadimitriou, C | 1 |
| Terpos, E | 1 |
| Dimopoulos, MA | 1 |
| Hillegonds, DJ | 1 |
| Sherer, JT | 1 |
| Adamus, AT | 1 |
| Uchida, J | 1 |
| Sugimura, K | 1 |
| Tamada, S | 1 |
| Nishisaka, N | 1 |
| Kumata, K | 1 |
| Iwai, Y | 1 |
| Ikemoto, S | 1 |
| Ezaki, K | 1 |
| Sanna, G | 1 |
| Preda, L | 1 |
| Bruschini, R | 1 |
| Cossu Rocca, M | 1 |
| Verri, E | 1 |
| Bellomi, M | 1 |
| Goldhirsch, A | 1 |
| Nole, F | 1 |
| McKeage, K | 1 |
| Plosker, GL | 1 |
| Glover, D | 1 |
| Harvey, H | 1 |
| Grabelsky, S | 1 |
| Zelenakas, K | 1 |
| Macerata, R | 1 |
| Tyrrell, CJ | 1 |
| Collinson, M | 1 |
| Madsen, EL | 1 |
| Ford, JM | 1 |
| Coleman, T | 1 |
| Clarke, NW | 3 |
| McClure, J | 3 |
| George, NJ | 3 |
| Harvey, HA | 1 |
| Boissier, S | 1 |
| Magnetto, S | 1 |
| Frappart, L | 1 |
| Cuzin, B | 1 |
| Ebetino, FH | 1 |
| Delmas, PD | 1 |
| Clezardin, P | 1 |
| Coleman, RE | 2 |
| Purohit, OP | 1 |
| Vinholes, JJ | 1 |
| Zekri, J | 1 |
| Berruti, A | 1 |
| Sperone, P | 1 |
| Fasolis, G | 1 |
| Torta, M | 1 |
| Fontana, D | 1 |
| Dogliotti, L | 1 |
| Angeli, A | 1 |
| Bloomfield, DJ | 1 |
| Broyles, DL | 1 |
| Nielsen, RG | 1 |
| Bussett, EM | 1 |
| Lu, WD | 1 |
| Mizrahi, IA | 1 |
| Nunnelly, PA | 1 |
| Ngo, TA | 1 |
| Noell, J | 1 |
| Christenson, RH | 1 |
| Kress, BC | 1 |
| Lortholary, A | 1 |
| Jadaud, E | 1 |
| Berthaud, P | 1 |
| Berenson, J | 1 |
| Hortobagyi, G | 1 |
| Olson, KB | 1 |
| Pienta, KJ | 1 |
| Leder, BZ | 1 |
| Fallon, MA | 3 |
| Lee, ML | 1 |
| Finkelstein, JS | 3 |
| Lee, MV | 1 |
| Fong, EM | 1 |
| Singer, FR | 1 |
| Guenette, RS | 1 |
| Jones, J | 1 |
| McGovern, FJ | 2 |
| Zietman, AL | 2 |
| Hayden, DL | 1 |
| Schoenfeld, DA | 2 |
| Kantoff, PW | 2 |
| Dawson-Hughes, B | 1 |
| Diamond, TH | 1 |
| Winters, J | 1 |
| Smith, A | 1 |
| De Souza, P | 1 |
| Kersley, JH | 1 |
| Lynch, WJ | 1 |
| Bryant, C | 1 |
| Sun, YC | 1 |
| Geldof, AA | 1 |
| Newling, DW | 1 |
| Rao, BR | 1 |
| Holbrook, IB | 1 |
| Nemoto, R | 1 |
| Sato, S | 1 |
| Nishijima, Y | 1 |
| Miyakawa, I | 1 |
| Koiso, K | 1 |
| Harada, M | 1 |
| Masud, T | 1 |
| Slevin, ML | 1 |
| Pelger, RC | 1 |
| Lycklama à Nijeholt, AA | 1 |
| Papapoulos, SE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Randomized Study of High-Dose Ketoconazole With or Without Alendronate Sodium in Patients With Androgen-Independent Metastastic Adenocarinoma of the Prostate[NCT00019695] | Phase 2 | 0 participants | Interventional | 1999-03-31 | Terminated | ||
| Atrasentan and Zometa for Men With Androgen Independent Prostate Cancer Metastatic to Bone: A Randomized Pilot Study[NCT00181558] | Phase 2 | 44 participants | Interventional | 2001-12-31 | Completed | ||
| A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men With Prostate Cancer Metastatic to Bone[NCT00079001] | Phase 3 | 645 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| A Randomized, Open Label, Active Controlled Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous Bisphosphonates[NCT00104650] | Phase 2 | 111 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Randomized Placebo-Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone Alone in Patients With Hormone Refractory Metastatic Prostate Cancer and Pain[NCT00003232] | Phase 3 | 227 participants (Actual) | Interventional | 1997-11-24 | Completed | ||
| A Phase III, Multicenter, Randomized, Controlled Study of Maximum Androgen Blockade With vs. Without Zoledronic Acid in Prostatic Cancer Patients With Metastatic Bone Disease[NCT00685646] | Phase 3 | 227 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| A Randomised Phase II Feasibility Study of Docetaxel (Taxotere®) Plus Prednisolone vs. Docetaxel (Taxotere®) Plus Prednisolone Plus Zoledronic Acid (Zometa®) vs. Docetaxel (Taxotere®) Plus Prednisolone Plus Strontium-89 vs. Docetaxel (Taxotere®) Plus Pred[NCT00554918] | Phase 2 | 300 participants (Anticipated) | Interventional | 2005-02-28 | Completed | ||
| A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer[NCT00321620] | Phase 3 | 1,904 participants (Actual) | Interventional | 2006-04-01 | Completed | ||
| A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41[NCT00216060] | Phase 3 | 63 participants (Actual) | Interventional | 2003-10-31 | Terminated (stopped due to Terminated due to low accrual) | ||
| STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial[NCT00268476] | Phase 2/Phase 3 | 11,992 participants (Actual) | Interventional | 2005-07-08 | Active, not recruiting | ||
| A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420] | Phase 1 | 4 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Hormonal Regulation of Circulating Endothelial Progenitor Cells and HDL-C in Men Title Changed With New Protocol (12/14/09): Hormonal Regulation of HDL-C in Men[NCT00729859] | Phase 2 | 31 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Randomized Controlled Clinical Trial of Carbohydrate Restriction Among Men Initiating Androgen Deprivation Therapy For Prostate Cancer[NCT00932672] | Phase 2 | 45 participants (Actual) | Interventional | 2009-06-30 | Terminated (stopped due to slow recruitment, lack of funding and PI transferred) | ||
| A Pilot Phase IV Study to Evaluate Variation in Bone Mineral Density, Lean and Fat Body Mass Index Measured by Dual-energy X-ray Absorptiometry in Patients With Prostate Cancer Without Bone Metastasis Treated With Degarelix[NCT03202381] | Phase 4 | 35 participants (Anticipated) | Interventional | 2017-06-26 | Recruiting | ||
| The Role of Akkermansia Muciniphilia in Combating the Metabolic Effects of Androgen Deprivation Therapy in Men With Metastatic Prostate Cancer[NCT05802121] | Early Phase 1 | 30 participants (Anticipated) | Interventional | 2023-06-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Overall survival (OS) was defined as the time from randomization to death of any cause. Surviving patients were censored at the date of last follow-up. The median OS with 95% CI was estimated using the Kaplan Meier method. (NCT00079001)
Timeframe: Up to 10 years
| Intervention | months (Median) |
|---|---|
| Zoledronic Acid + Androgen Deprivation Therapy | 37.9 |
| Placebo + Androgen Deprivation Therapy | 36.0 |
"Progression Free Survival (PFS) was defined as the time from registration until disease progression or death, whichever occurs first. The median PFS with 95% CI was estimated using the Kaplan-Meier method.~Progression is defined as one or more of the following: new bone metastases, biochemical progression of PSA, treatment with radiation therapy while on treatment." (NCT00079001)
Timeframe: Up to 10 years
| Intervention | months (Median) |
|---|---|
| Zoledronic Acid + Androgen Deprivation Therapy | 10.6 |
| Placebo + Androgen Deprivation Therapy | 9.2 |
Time to first skeletal related event (SRE) was defined as the time from randomization to first skeletal event. Skeletal events are defined as radiation to bone, clinical fracture, surgery to bone and spinal cord compression and death due to prostate cancer. The median with 95% CI was estimated using the Kaplan Meier method. (NCT00079001)
Timeframe: Up to 10 years
| Intervention | months (Median) |
|---|---|
| Zoledronic Acid + Androgen Deprivation Therapy | 31.9 |
| Placebo + Androgen Deprivation Therapy | 28.8 |
Time from the 1st occurrence of uNTx below 50 nmol BCE/mmol (corrected by creatinine) to the 1st occurrence of uNTx above 50 nmol BCE/mmol up to week 25. For participants who remained below 50 nmol BCE/mmol, the time is censored at the time of last evaluation of uNTx up to week 25. (NCT00104650)
Timeframe: Day 1, week 25
| Intervention | Participants (Number) |
|---|---|
| Bisphosphonate IV Q4W | 25 |
| Denosumab 180 mg Q12W | 32 |
| Denosumab 180 mg Q4W | 35 |
Occurrence of hypercalcemia at grade 3 or 4 according to CTCAE v3 criteria (NCT00104650)
Timeframe: Day 1, week 25
| Intervention | Participants (Number) |
|---|---|
| Bisphosphonate IV Q4W | 0 |
| Denosumab 180 mg Q12W | 0 |
| Denosumab 180 mg Q4W | 0 |
Percent change from baseline to week 25 in Type I serum C-Telopeptide (CTX), calculated using ((week 25 value - baseline value) / baseline value ) x 100. (NCT00104650)
Timeframe: Baseline, week 25
| Intervention | Percent change (Mean) |
|---|---|
| Bisphosphonate IV Q4W | -40.68 |
| Denosumab 180 mg Q12W | -76.74 |
| Denosumab 180 mg Q4W | -68.39 |
Percent change from baseline to week 25 urinary N-telopeptide (uNTX) calculated using ((week 25 value - baseline value) / baseline value ) x 100. (NCT00104650)
Timeframe: Baseline, week 25
| Intervention | Percent change (Mean) |
|---|---|
| Bisphosphonate IV Q4W | -32.91 |
| Denosumab 180 mg Q12W | -69.09 |
| Denosumab 180 mg Q4W | -41.68 |
Skeletal Related Event (SRE), defined as >1 of the following: pathological bone fracture, spinal cord compression, surgery or radiation therapy to bone (including the use of radioisotopes). (NCT00104650)
Timeframe: Day 1, week 25
| Intervention | Participants (Number) |
|---|---|
| Bisphosphonate IV Q4W | 6 |
| Denosumab 180 mg Q12W | 4 |
| Denosumab 180 mg Q4W | 2 |
Time from study day 1 to first Skeletal Related Event (SRE), defined as >1 of the following: pathological bone fracture, spinal cord compression, surgery or radiation therapy to bone (including the use of radioisotopes). (NCT00104650)
Timeframe: Day 1, week 25
| Intervention | Participants (Number) |
|---|---|
| Bisphosphonate IV Q4W | 6 |
| Denosumab 180 mg Q12W | 4 |
| Denosumab 180 mg Q4W | 2 |
Kaplan-Meier estimate of the median time from enrollment to the 1st occurrence of uNTx below 50 nmol BCE/mmol (corrected by creatinine) up to week 25. For participants whose uNTx does not go below 50 nM BCE/mM creatinine, the time is censored at time of last evaluation of uNTx by week 25. (NCT00104650)
Timeframe: Day 1, week 25
| Intervention | Days (Median) |
|---|---|
| Bisphosphonate IV Q4W | 65 |
| Denosumab 180 mg Q12W | 9 |
| Denosumab 180 mg Q4W | 10 |
Urinary N-telopeptide (uNTx) corrected by creatinine (uNTx/Cr) < 50 nmol/mmol at week 13. (NCT00104650)
Timeframe: 13 weeks
| Intervention | Participants (Number) |
|---|---|
| Bisphosphonate IV Q4W | 10 |
| Denosumab 180 mg Q12W | 21 |
| Denosumab 180 mg Q4W | 28 |
Urinary N-telopeptide (uNTX) corrected by creatinine < 50 nmol/mmol at week 25. (NCT00104650)
Timeframe: 25 weeks
| Intervention | Participants (Number) |
|---|---|
| Bisphosphonate IV Q4W | 13 |
| Denosumab 180 mg Q12W | 21 |
| Denosumab 180 mg Q4W | 23 |
Time to the first on-study skeletal-related event (SRE) analyzed for non-inferiority. Kaplan-Meier estimates of the median and its dispersion are reported. (NCT00321620)
Timeframe: Up to 40.5 months
| Intervention | Days (Median) |
|---|---|
| Zoledronic Acid | 521.0 |
| Denosumab | 629.0 |
Time to the first on-study skeletal-related event (SRE), analyzed for superiority of denosumab. Kaplan-Meier estimates of the median and its dispersion are reported. (NCT00321620)
Timeframe: Up to 40.5 months
| Intervention | Days (Median) |
|---|---|
| Zoledronic Acid | 521.0 |
| Denosumab | 629.0 |
"Time to the first-and-subsequent on-study skeletal-related event (SRE), analyzed for superiority of denosumab using multiple event analysis, the event must occur at least 21 days after the previous SRE.~This outcome measure utilizes multiple event times, was analyzed based on a proportional mean model, and is therefore more appropriately summarized by the cumulative mean number of events." (NCT00321620)
Timeframe: Up to 40.5 months
| Intervention | Events (Number) |
|---|---|
| Zoledronic Acid | 584 |
| Denosumab | 494 |
Number of participants experiencing a SRE(skeletal-related event) or death occurred, cumulative from each arm ( a daily oral dose of 30 mg risedronate, or placebo) (NCT00216060)
Timeframe: 36 months
| Intervention | participants (Number) |
|---|---|
| Risedronate Arm | 11 |
| Placebo Arm | 13 |
(NCT00216060)
Timeframe: 36 months
| Intervention | percentage of participants (Number) |
|---|---|
| Risedronate Arm | 50 |
| Placebo Arm | 29 |
(NCT00216060)
Timeframe: 36 months
| Intervention | percentage of participants (Number) |
|---|---|
| Risedronate | 72.5 |
| Placebo | 71.5 |
"Urine total DPD median in response to treatment on both study arms at week 24. compare median from baseline and week 24.~Deoxypyridinoline (DPD) is measured in hydrolyzed urine samples using high-performance liquid chromatography technique. After extraction of the cross-links and elimination of the urine impurities by a Bio-Rad SPE cartridge (Bio-Rad Laboratories, Hercules, CA), total DPD is eluted from reverse-phase high-performance liquid chromatography by ion pair chromatography with isocratic elution.~The compounds are detected as a result of their natural fluorescence with a fluorescence detector" (NCT00216060)
Timeframe: 24 weeks
| Intervention | nmol/mmol creatinine (Median) | |
|---|---|---|
| week 24 | baseline | |
| Placebo Arm | 12.62 | 10.12 |
| Risedronate Arm | 6.91 | 8.83 |
Serum BAP median changes between baseline and week 24. The Ostase assays are performed with an access immunoassay system, which is an assay of serum samples that provides a quantitative measurement of bone alkaline phosphatase (BAP). A mouse monoclonal antibody specific to BAP is added to a re-action vessel with paramagnetic particles coated with goat antimouse polyclonalantibody.Calibrators,controls,andsamplescontainingBAP are added to the coated particles and bind to the anti-BAP monoclonal antibody. After the formation of a solid phase/capture antibody/BAP complex, separation in a magnetic field and washing remove materials not bound to the solid phase. A chemiluminescent substrate, LumiPhos 530, is added to the reaction vessel, and light generated by the reaction is measured with a luminometer. The light production is directly proportional to the concentration of BAP in the sample. The amount of analyte in thesample is determined from a stored multipoint calibration curve (NCT00216060)
Timeframe: 24 week
| Intervention | ng/mL (Median) | |
|---|---|---|
| 24 week | baseline | |
| Placebo Arm | 13.16 | 19.50 |
| Risedronate Arm | 9.5 | 20.95 |
Serum Osteocalcin (OC) medians between baseline and 24 weeks areperformed with the Elecsys 2010 automated analyzer, which uses an electrochemiluminescence immunoassay technique for the in vitro quantitative determination of serum total osteocalcin in humanserum. The assay uses a sandwich test principle in which afirst biotinylated monoclonal antibody recognizing N-MID osteocalcin and a second monoclonal antibody against N-MID osteocalcin labeled with ruthenium are incubated with 20mL of serum. After a first incubation, streptavidin-coated microparticles are added for a second incubation, and the complex becomes bound to the solid phase by interaction of biotin and streptavidin.These microparticles are then magnetically captured onto the surface of an electrode. Application of a voltage on this electrode induces chemiluminescent emission, which is measured by a photomultiplierand compared with a calibration curve that is generated in aninstrument-specific manner by 2-point calibration. (NCT00216060)
Timeframe: 24 week
| Intervention | ug/L (Median) | |
|---|---|---|
| at 24 week | baseline | |
| Placebo Arm | 27.35 | 18.24 |
| Risedronate Arm | 11.88 | 20.08 |
"Urine N-telopeptide (NTX) median changes between baseline and week 24. The assays are performed with the NTx Reagent Pack kit from Ortho-Clinical Diagnostics (Ortho-Clinical Diagnostics/Johnson & Johnson, Amersham, UK), which is a kit designed for the quantitative determination of N-terminal telopeptide (NTx) in human urine on the automated Vitros Immunodiagnostic System ECi (Ortho-Clinical Diagnostics/Johnson & Johnson, Amersham, UK). A competitive immunoassay technique is used. This depends on competition between NTx present in the sample and a synthetic NTx peptide coated on the wells for binding by a horseradish peroxidase (HRP)-labeled antibody conjugate (mouse monoclonal anti-NTx). The conjugate is captured by the peptide coated on the wells; unbound materials are removed by washing.~The bound HRP conjugate is measured by a luminescent reaction." (NCT00216060)
Timeframe: 24 week
| Intervention | nmol BCE/mmol creatinine (Median) | |
|---|---|---|
| at 24 week | baseline | |
| Placebo Arm | 62.95 | 48.08 |
| Risedronate Arm | 20.63 | 41.33 |
Number of CD33 + CD134+ cells as a percentage of all lymphocytes (NCT00729859)
Timeframe: Baseline, Day 28
| Intervention | percentage of all lymphocytes (Mean) | |
|---|---|---|
| Baseline | Day 28 | |
| Group 1: Acyline + Placebo Gel + Placebo Pill | 0.101 | 0.081 |
(NCT00729859)
Timeframe: Baseline, Day 28
| Intervention | pmol/L (Mean) | |
|---|---|---|
| Baseline | Day 28 | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 95.4 | 31.9 |
| Group 2: Acyline, Testosterone Gel | 117.8 | 109.0 |
| Group 3: Acyline, Testosterone Gel, Anastrozole Pill | 96.3 | 36.5 |
(NCT00729859)
Timeframe: Baseline, Day 28, Day 56
| Intervention | mmol/L (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total cholesterol Day 0 | Total cholesterol Day 28 | Total cholesterol Day 56 | LDL choesterol Day 0 | LDL cholesterol Day 28 | LDL cholesterol Day 56 | HDL cholesterol Day 0 | HDL cholesterol Day 28 | HDL cholesterol Day 56 | Triglycerides Day 0 | Triglycerides Day 28 | Triglycerides Day 56 | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 4.97 | 5.44 | 4.95 | 2.95 | 3.29 | 2.87 | 1.19 | 1.37 | 1.19 | 1.79 | 1.73 | 1.89 |
| Group 2: Acyline, Testosterone Gel, Placebo Pill | 4.48 | 4.51 | 4.14 | 2.77 | 2.80 | 2.49 | 1.32 | 1.32 | 1.32 | 0.82 | 0.86 | 0.80 |
| Group 3: Acyline, Testosterone Gel, Oral Anastrozole | 4.56 | 4.56 | 4.27 | 2.67 | 2.75 | 2.51 | 1.40 | 1.32 | 1.30 | 1.08 | 1.08 | 1.02 |
(NCT00729859)
Timeframe: Baseline, Day 28, Day 56
| Intervention | picomolar (Mean) | ||
|---|---|---|---|
| Baseline | Day 28 | Day 56 | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 54 | 69 | 54 |
| Group 2: Acyline, Testosterone Gel, Placebo Pill | 65 | 59 | 64 |
| Group 3: Acyline, Testosterone Gel, Oral Anastrozole | 50 | 42 | 50 |
(NCT00729859)
Timeframe: Baseline, 28 days
| Intervention | IU/L (Mean) | |
|---|---|---|
| Baseline | Day 28 | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 4.2 | 0.42 |
| Group 2: Acyline, Testosterone Gel | 2.9 | 0.39 |
| Group 3: Acyline, Testosterone Gel, Anastrazole Pill | 2.5 | 0.87 |
HOMA IR is a measure of insulin sensitivity calculated using fasting insulin and glucose concentration in a participants blood. Higher HOMA IR numbers are associated with increased insulin resistance and decreased insulin sensitivity. (NCT00729859)
Timeframe: Baseline, Day 28, Day 56
| Intervention | HOMA score (Mean) | ||
|---|---|---|---|
| Baseline | Day 28 | Day 56 | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 1.8 | 2.4 | 2.2 |
| Group 2: Acyline, Testosterone Gel, Placebo Pill | 2.0 | 1.9 | 1.9 |
| Group 3: Acyline, Testosterone Gel, Oral Anastrozole | 1.6 | 1.4 | 1.7 |
(NCT00729859)
Timeframe: Baseline, Day 28
| Intervention | IU/L (Mean) | |
|---|---|---|
| Baseline | Day 28 | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 4.3 | 0.31 |
| Group 2: Acyline, Testosterone Gel | 4.7 | 0.69 |
| Group 3: Acyline, Testosterone Gel, Anastrozole | 4.4 | 1.55 |
QUICKI is a measure of insulin sensitivity calculated using fasting insulin and glucose concentration in a participants blood. Higher QUICKI are associated with decreased insulin resistance and increased insulin sensitivity. (NCT00729859)
Timeframe: Baseline, Day 28, Day 56
| Intervention | QUICKI index (Mean) | ||
|---|---|---|---|
| Baseline | Day 28 | Day 56 | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 0.36 | 0.34 | 0.35 |
| Group 2: Acyline, Testosterone Gel, Placebo Pill | 0.35 | 0.35 | 0.35 |
| Group 3: Acyline, Testosterone Gel, Oral Anastrozole | 0.36 | 0.38 | 0.36 |
(NCT00729859)
Timeframe: Baseline, Day 28
| Intervention | nmol/L (Mean) | |
|---|---|---|
| Baseline | Day 28 | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 34.9 | 37.5 |
| Group 2: Acyline, Testosterone Gel | 23.0 | 22.1 |
| Group 3: Acyline, Testosterone Gel, Anastrozole Pill | 27.6 | 25.1 |
(NCT00729859)
Timeframe: Baseline, Day 28
| Intervention | nmol/L (Mean) | |
|---|---|---|
| Baseline testosterone concentration | Day 28 testosterone concentration | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 15.4 | 0.8 |
| Group 2: Acyline, Testosterone Gel | 16.3 | 17.8 |
| Group 3: Acyline, Testosterone Gel, Anastrozole | 16.5 | 19.0 |
10 reviews available for pamidronate and Prostatic Neoplasms
| Article | Year |
|---|---|
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis.
Topics: Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; | 2013 |
Antitumor effects of bisphosphonates: from the laboratory to the clinic.
Topics: Antineoplastic Agents; Apoptosis; Bone Density Conservation Agents; Breast Neoplasms; Cell Adhesion | 2011 |
Bone-targeted agents: preventing skeletal complications in prostate cancer.
Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Bone Density; Bone Neoplasms; Clinical Tria | 2012 |
The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
Topics: Adenocarcinoma; Biomarkers; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonat | 2002 |
Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints.
Topics: Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Data Interpretation, Statistical; Diphosphonates; | 2002 |
Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neop | 2008 |
Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review.
Topics: Analgesics, Non-Narcotic; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Evidence | 1998 |
[Bisphosphonates and bone metastases].
Topics: Antineoplastic Agents; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonat | 1999 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasm | 2000 |
15 trials available for pamidronate and Prostatic Neoplasms
| Article | Year |
|---|---|
Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event.
Topics: Aged; Alkaline Phosphatase; Amino Acids; Androgen Antagonists; Antibodies, Monoclonal, Humanized; Bi | 2014 |
Risk of skeletal-related events in patients with advanced prostate cancer treated with pamidronate or zoledronic acid.
Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Humans | 2010 |
Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Double-Blind | 2003 |
Palliative treatment of bone metastases in hormone-refractory prostate cancer: effects of pamidronate on the carboxyterminal telopeptide of type-I collagen level in patients with increasing prostate-specific antigen levels.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Collagen Type | 2007 |
Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Dose-Response Rela | 1994 |
Intravenous pamidronate: infusion rate and safety.
Topics: Adult; Aged; Breast Neoplasms; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Drug Ad | 1994 |
The effects of orchidectomy on skeletal metabolism in metastatic prostate cancer.
Topics: Biopsy; Bone and Bones; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Humans; Male; Orc | 1993 |
The role of bisphosphonates in the treatment of bone metastases--the U.S. experience.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; | 1996 |
High dose pamidronate: clinical and biochemical effects in metastatic bone disease.
Topics: Biomarkers, Tumor; Bone Diseases; Breast Neoplasms; Collagen; Diphosphonates; Female; Humans; Male; | 1997 |
Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Amino Acids; Antineoplastic Agents, Hormonal; Biomark | 2001 |
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Bone Density; Bone Resorption; Diphosphonates; Femur; Gonadot | 2001 |
The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Density; Cr | 2001 |
Changes in body composition during androgen deprivation therapy for prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic C | 2002 |
Changes in body composition during androgen deprivation therapy for prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic C | 2002 |
Changes in body composition during androgen deprivation therapy for prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic C | 2002 |
Changes in body composition during androgen deprivation therapy for prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic C | 2002 |
Changes in body composition during androgen deprivation therapy for prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic C | 2002 |
Changes in body composition during androgen deprivation therapy for prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic C | 2002 |
Changes in body composition during androgen deprivation therapy for prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic C | 2002 |
Changes in body composition during androgen deprivation therapy for prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic C | 2002 |
Changes in body composition during androgen deprivation therapy for prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic C | 2002 |
Changes in body composition during androgen deprivation therapy for prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic C | 2002 |
Changes in body composition during androgen deprivation therapy for prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic C | 2002 |
Changes in body composition during androgen deprivation therapy for prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic C | 2002 |
Changes in body composition during androgen deprivation therapy for prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic C | 2002 |
Changes in body composition during androgen deprivation therapy for prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic C | 2002 |
Changes in body composition during androgen deprivation therapy for prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic C | 2002 |
Changes in body composition during androgen deprivation therapy for prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic C | 2002 |
Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer.
Topics: Alkaline Phosphatase; Bone Neoplasms; Bone Resorption; Calcium; Creatinine; Diphosphonates; Humans; | 1992 |
Osteoclast inhibition by pamidronate in metastatic prostate cancer: a preliminary study.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Bone and Bones; Diphosphonates; Humans; Hydroxyproline; | 1991 |
44 other studies available for pamidronate and Prostatic Neoplasms
| Article | Year |
|---|---|
Repeated systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells efficiently control tumor development in vivo.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Diphosphonates; Drug Administration Schedule; Humans; Imm | 2013 |
Effects of bisphosphonates in combination with ionizing radiation and antioxidants on the growth of prostate and melanoma cells lines.
Topics: Animals; Antioxidants; Apigenin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modal | 2013 |
Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Hu | 2014 |
Time and labor costs associated with administration of intravenous bisphosphonates for breast or prostate cancer patients with metastatic bone disease: a time and motion study.
Topics: Aged; Ambulatory Care; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Canada; C | 2014 |
Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Fem | 2015 |
Acute retinal pigment epithelial detachment secondary to pamidronate administration.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Fluorescein Angiography; Humans; I | 2009 |
[Efficiency of second-generation bisphosphonate in treating patients with prostate cancer and bone metastases].
Topics: Bone Neoplasms; Diphosphonates; Humans; Male; Pamidronate; Prostatic Neoplasms; Treatment Outcome | 2008 |
Indirect antitumor effects of bisphosphonates on prostatic LNCaP cells co-cultured with bone cells.
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Cell Proliferation; Coculture Tech | 2009 |
Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; | 2009 |
Protein kinase C is inhibited by bisphosphonates in prostate cancer PC-3 cells.
Topics: Animals; Cell Line, Tumor; Diphosphonates; Enzyme Stability; Gene Expression Regulation, Neoplastic; | 2010 |
Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; | 2009 |
Pamidronate inhibits antiapoptotic bcl-2 expression through inhibition of the mevalonate pathway in prostate cancer PC-3 cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Diphosphonates; Drug Synergism; Gene Expression | 2010 |
Nephrotic syndrome induced by pamidronate.
Topics: Adenocarcinoma; Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Huma | 2011 |
Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Neoplasms; Bre | 2010 |
Investigation of bone disease using isomerized and racemized fragments of type I collagen.
Topics: Adult; Aged; Biomarkers; Bone Diseases; Bone Neoplasms; Bone Resorption; Cells, Cultured; Collagen; | 2003 |
Bisphosphonates for RSDS and prostate cancer--more benefit then revealed!
Topics: Analgesics, Non-Narcotic; Clodronic Acid; Controlled Clinical Trials as Topic; Diphosphonates; Doubl | 2002 |
Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results.
Topics: Antineoplastic Agents; Autopsy; Bone Neoplasms; Diphosphonates; Humans; Infusions, Intravenous; Male | 2003 |
Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Caspase 3; Caspases; Cell Membrane; Cell Surviv | 2003 |
Bisphosphonates in prostate cancer: where are we and where should we go?
Topics: Administration, Oral; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone | 2003 |
Orbital inflammatory disease after pamidronate treatment for metastatic prostate cancer.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Male; | 2003 |
Lack of efficacy of the combination of pamidronate and vitamin D on regression of prostate cancer in the Dunning rat model.
Topics: Animals; Anti-Inflammatory Agents; Diphosphonates; Disease Models, Animal; Drug Therapy, Combination | 2003 |
Bisphosphonates for men with prostate cancer: sifting through the rubble.
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Double-Blind Method; Humans; Male; Pain; Pall | 2003 |
Posterior uveitis: an under-recognized adverse effect of pamidronate: 2 case reports.
Topics: Bone Neoplasms; Bone Resorption; Carcinoma; Conjunctivitis; Diphosphonates; Fatal Outcome; Humans; M | 2003 |
Pamidronate, hypocalcemia, and calcium and vitamin D supplementation.
Topics: Bone Neoplasms; Confounding Factors, Epidemiologic; Diphosphonates; Humans; Hypocalcemia; Male; Pami | 2004 |
Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Calcium; Carrier | 2005 |
Safety of long-term administration of bisphosphonates in elderly cancer patients.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration S | 2004 |
Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
Topics: Analgesics; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Fractures, Bone; Humans; Imidazol | 2005 |
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
Topics: Abscess; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breas | 2005 |
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neopla | 2005 |
The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Calcium; Cell Line, Tumor; Diphosphonates | 2006 |
Outcomes of patients with prostate cancer receiving zoledronic acid or pamidronate for prevention of skeletal-related events.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Cohort Studies; Diphosphonates; Huma | 2007 |
The role of surgery in jaw bone necrosis associated with long-term use of bisphosphonates.
Topics: Adenocarcinoma; Bone Neoplasms; Bone Plates; Bone Screws; Breast Neoplasms; Cutaneous Fistula; Dipho | 2008 |
Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices.
Topics: Bone Matrix; Bone Neoplasms; Breast Neoplasms; Calcification, Physiologic; Cell Adhesion; Cell Adhes | 1997 |
Pamidronate administration improves the secondary hyperparathyroidism due to "Bone Hunger Syndrome" in a patient with osteoblastic metastases from prostate cancer.
Topics: Aged; Alkaline Phosphatase; Bone and Bones; Bone Neoplasms; Calcium; Collagen; Diphosphonates; Human | 1997 |
Analytical and clinical performance characteristics of Tandem-MP Ostase, a new immunoassay for serum bone alkaline phosphatase.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone and Bones; Bone Diseases; Bon | 1998 |
Use of bisphosphonates in the treatment of prostate cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Male; Pain; Palliative Care; Pamidron | 2000 |
Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM).
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcem | 2000 |
Bisphosphonate treatment inhibits the growth of prostate cancer cells.
Topics: Antineoplastic Agents; Cell Cycle; Cell Division; Cell Survival; Diphosphonates; Growth Inhibitors; | 2001 |
Bisphosphonates may be useful in treatment of bone metastases.
Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials a | 2001 |
Bone loss accompanying medical therapies.
Topics: Administration, Inhalation; Antineoplastic Agents, Hormonal; Bone Density; Bone Resorption; Diphosph | 2001 |
Progression delay of prostate tumor skeletal metastasis effects by bisphosphonates.
Topics: Animals; Bone Neoplasms; Clodronic Acid; Diphosphonates; Male; Pamidronate; Prostatic Neoplasms; Rat | 1992 |
Effects of a new bisphosphonate (AHBuBP) on osteolysis induced by human prostate cancer cells in nude mice.
Topics: Adenocarcinoma; Alendronate; Animals; Diphosphonates; Etidronic Acid; Humans; Male; Mice; Mice, Nude | 1990 |
Pamidronate to reduce bone pain in normocalcaemic patient with disseminated prostatic carcinoma.
Topics: Adenocarcinoma; Calcium; Diphosphonates; Humans; Male; Middle Aged; Pain Measurement; Pain, Intracta | 1989 |
Short-term metabolic effects of pamidronate in patients with prostatic carcinoma and bone metastases.
Topics: Bone and Bones; Bone Neoplasms; Bone Resorption; Calcium; Diphosphonates; Humans; Male; Pamidronate; | 1989 |